Palantir Technologies Stock - UBS reiterates Buy rating and $200 target
17.06.2026 - 20:25:58 | ad-hoc-news.de
Edited by ad hoc news Analyst & Consensus Desk. Verified prior to publication on 06/17/2026, 20:25 CET. Details in the imprint.
Palantir Technologies (US69608A1088) stays on Wall Street’s radar after UBS reiterated its Buy rating and $200 price target, according to an update cited by Investing.com. Investing.com highlights the latest UBS view on Palantir The call keeps the data analytics and AI software group firmly in the high-expectations bracket.
All news and analysis on Palantir Technologies stock
Recent analyst calls and earnings have kept Palantir Technologies in focus for investors watching AI and software platforms.
What UBS is signaling
The UBS stance underscores that at least part of the analyst community still sees upside in Palantir despite a demanding valuation. Investing.com reports the bank kept a Buy rating alongside a $200 price target, pointing to continued AI-driven growth potential. The UBS note is summarized in the Palantir news feed on Investing.com
While the detailed UBS model is not public, the reiterated target sits well above recent trading levels on Nasdaq. That implies the bank expects Palantir to deepen its footprint in government and commercial AI applications over the next few years.
How consensus views the stock
Palantir stock divides opinion. A recent video breakdown citing Simply Wall Street data put the shares at roughly 135 times trailing earnings versus an estimated fair price-earnings ratio of about 59, highlighting a rich multiple even by AI standards. A YouTube analysis discusses valuation metrics and consensus targets
That same analysis noted that a discounted cash-flow model suggested fair value around $135 per share, while the analyst consensus fair value was cited at about $182.75 based on estimates from 27 analysts. The spread illustrates how wide the valuation debate has become.
What the numbers show
Fundamentals have strengthened. An analysis on Seeking Alpha pointed out that Palantir’s Q1 2026 revenue reached roughly $1.28 billion, with US revenue up 104% year on year, while net income margins have scaled to around the low-50% range in recent quarters. A Seeking Alpha article reviews Palantir’s latest quarterly figures
Higher profitability gives analysts more room to justify aggressive targets, but it also hardens expectations. Any slowdown in AI contract wins, especially in the US commercial segment, could quickly challenge the more optimistic valuation cases.
The role of AI optimism
Palantir remains grouped with high-profile AI beneficiaries in US markets. Its narrative is tied to the idea that enterprises and governments will standardize on platforms like Palantir Foundry to run critical, data-heavy workflows in defense, healthcare and manufacturing.
For bullish analysts, the combination of strong margins, sticky software subscriptions and rising US commercial adoption supports premium pricing. More cautious houses tend to flag execution risks and the possibility that AI spending normalizes from current elevated levels.
The product behind the stock
Palantir makes money primarily by selling its Gotham and Foundry software platforms, which help customers integrate, manage and analyze large data sets. More recently, the company has pushed its Artificial Intelligence Platform to bundle data integration with generative AI tools for enterprises.
Where the stock trades today
The shares of Palantir Technologies (US69608A1088) trade on Nasdaq at $133.25 as of 06/16/2026, 22:00 ET.
Key facts on Palantir Technologies stock
- Company: Palantir Technologies Inc.
- ISIN: US69608A1088
- Ticker: PLTR
- Venue: Nasdaq
- Price (as of 06/16/2026, 22:00 ET): 133.25 USD
- Market cap: 319.44 billion USD (as of 06/16/2026)
- Sector / Industry: Information Technology / Software
- Index membership: S&P 500
- Next earnings date: 08/03/2026
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
